Regenxbio Inc (NASDAQ:RGNX) SVP Curran Simpson sold 62,309 shares of the stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $60.85, for a total transaction of $3,791,502.65. Following the completion of the transaction, the senior vice president now directly owns 86,017 shares of the company’s stock, valued at approximately $5,234,134.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Regenxbio stock opened at $62.42 on Friday. Regenxbio Inc has a 1 year low of $23.25 and a 1 year high of $85.10. The company has a market capitalization of $2.00 billion, a PE ratio of -25.48, a PEG ratio of 12.40 and a beta of -1.19.
Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.23 by ($0.93). Regenxbio had a net margin of 44.44% and a return on equity of 28.70%. The firm had revenue of $40.03 million during the quarter, compared to analyst estimates of $100.00 million. Analysts expect that Regenxbio Inc will post 1.64 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in RGNX. BlackRock Inc. increased its stake in shares of Regenxbio by 89.9% in the second quarter. BlackRock Inc. now owns 4,218,413 shares of the biotechnology company’s stock valued at $302,671,000 after buying an additional 1,997,447 shares during the period. Marshall Wace LLP acquired a new position in shares of Regenxbio in the second quarter valued at approximately $14,712,000. RTW Investments LP increased its stake in shares of Regenxbio by 10.7% in the second quarter. RTW Investments LP now owns 2,079,555 shares of the biotechnology company’s stock valued at $149,208,000 after buying an additional 201,788 shares during the period. Voya Investment Management LLC increased its stake in shares of Regenxbio by 1,514.5% in the second quarter. Voya Investment Management LLC now owns 203,557 shares of the biotechnology company’s stock valued at $14,605,000 after buying an additional 190,949 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Regenxbio by 140.6% in the second quarter. Bank of New York Mellon Corp now owns 319,330 shares of the biotechnology company’s stock valued at $22,911,000 after buying an additional 186,595 shares during the period. 80.81% of the stock is owned by institutional investors.
A number of research firms have recently commented on RGNX. ValuEngine cut shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Barclays increased their target price on shares of Regenxbio from $48.00 to $83.00 and gave the stock an “overweight” rating in a report on Monday, August 13th. Chardan Capital increased their target price on shares of Regenxbio from $90.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, July 16th. Raymond James increased their target price on shares of Regenxbio from $76.00 to $96.00 and gave the stock an “outperform” rating in a report on Friday, September 7th. Finally, BidaskClub cut shares of Regenxbio from a “buy” rating to a “hold” rating in a report on Friday, October 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $77.64.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Further Reading: What is a put option?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.